A Phase 2 of VIB7734 for the Treatment of Moderate to Severely Active SLE (RECAST SLE)

First filed June, 2021, Updated June, 2021; Recruiting
CATEGORIES: General SLE

The purpose of this  Phase 2 randomized, double-blind, placebo-controlled study is to study the safety and efficacy of VIB7734 for the treatment of moderate to severely active Systemic Lupus Erythematosus in approximately 195 participants.

This study is being offered at 7 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance.

To Learn More Contact
Horizon Therapeutics1-866-479-6742 or visit clinicaltrials@horizontherapeutics.com
ClinicalTrials.gov identifier (NCT number): NCT04925934

Learn More